Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.45 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.39 |
| ▸ | CLK2 | P49760 | 3/20 | 0.39 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30323242 | 1.00 | MAPT (0.53) | MAPTSMN1; SMN2HTTKMT2ALMNA | |
| SCHEMBL422306 | 0.79 | MRGPRX1 (0.47) | MAPTSMN1; SMN2HTTKMT2ALMNA | |
| SCHEMBL2185553 | 0.79 | MAPT (0.56) | MAPTSMN1; SMN2HTTKMT2ALMNA | |
| SCHEMBL1604974 | 0.78 | MRGPRX1 (0.46) | MAPTSMN1; SMN2HTTKMT2ALMNA | |
| SCHEMBL868188 | 0.78 | MAPT (0.60) | MAPTSMN1; SMN2HTTKMT2ALMNA | |
| SCHEMBL2369413 | 0.77 | HTT (0.57) | MAPTSMN1; SMN2HTTKMT2ALMNA | |
| SCHEMBL899715 | 0.76 | MAPT (0.53) | MAPTSMN1; SMN2HTTKMT2ALMNA | |
| SCHEMBL14293290 | 0.76 | MAPT (0.53) | MAPTSMN1; SMN2HTTKMT2ALMNA | |
| SCHEMBL1901292 | 0.76 | MAP4K4 (0.53) | SMN1; SMN2HTTMRGPRX1PIP4K2CIRAK4 | |
| SCHEMBL2185527 | 0.76 | SMN1; SMN2 (0.58) | MAPTSMN1; SMN2HTTKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250017935-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-01-16 | — | — | US | disclosed |
| CN-118239926-A | TLR7 and 8 inhibitors, preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3761980-B1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-1018514-B1 | NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-6734180-B1 | NF-κB inhibitor comprising an indan derivative as an active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-05-11 | — | — | US | disclosed |
| US-6703421-B1 | ADMINISTERING NF-KAPPA B INHIBITOR | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| WO-2004014850-A2 | SUBSTITUTED AMINOPYRIMIDINES AS NEUROKININ ANTAGONISTS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1165566-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASE | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| CN-1105116-C | Thienopyrimidines with PDE V-inhibiting action | MERCK PATENT GMBH (DE) | 2003-04-09 | — | — | CN | disclosed |
| EP-1132093-A1 | PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-KAPPA B INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-6169091-B1 | TREATMENT OF PSORIASIS, FIBROSIS, ATHEROSCLEROSIS, RESTENOSIS, AUTO-IMMUNE DISEASE, ALLERGY, ASTHMA | GLAXO WELLCOME INC. | 2001-01-02 | — | — | US | disclosed |
| EP-1018514-A1 | NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0452002-A2 | Thienopyrimidine derivatives | DOWELANCO (US) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | MAPT 3696/4885SMN1; SMN2 1107/4885HTT 4359/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | MAPT 3892/4885SMN1; SMN2 1788/4885HTT 4570/4885 |
| US-20250017935-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM5, CHRM4, CHRM1 | MAPT 745/4885SMN1; SMN2 1744/4885HTT 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.